Experience
Ariad Pharmaceuticals
Eli Lilly and Company
Finnegan successfully represented Eli Lilly in connection with a lawsuit brought by Ariad Pharmaceuticals, accusing Lilly’s Xigris® product of infringing Ariad’s patent covering “NF-κB” technology. After a full en banc hearing, the U.S. Court of Appeals for the Federal Circuit held Ariad’s patent invalid under 35 U.S.C. § 112 for failing to comply with the written description requirement.
Ariad Pharmaceuticals v. Eli Lilly and Company, 08-1248, Fed. Cir., Judges Michel, Newman, Mayer, Lourie, Rader, Bryson, Gajarsa, Linn, Dyk, Prost, Moore
Ariad Pharmaceuticals v. Eli Lilly and Company, 1:02-cv-11280, D. Mass., Judge Zobel
Eli Lilly and Company
The Hillman Group, Inc. v. KeyMe, LLC
The Hillman Group, Inc.
Monta Vista
Placeware, Inc.
GlaxoSmithKline
Zymogenetics, Inc. v. Immunex Corp.
Immunex Corp.
Urologix Inc. v. Prostalund AB
ACMI Circon Corp.
GlaxoSmithKline
L'Oreal S.A. v. Clairol Inc. and Estee Lauder, Inc.
L'Oreal, S.A.
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.